| Literature DB >> 25502812 |
Nathan R Riding1, Nabeel Sheikh2, Carmen Adamuz3, Victoria Watt3, Abdulaziz Farooq4, Gregory P Whyte5, Keith P George5, Jonathan A Drezner6, Sanjay Sharma2, Mathew G Wilson7.
Abstract
BACKGROUND: An increasing number of sporting bodies report unacceptably high levels of false-positive ECGs when undertaking pre-participation cardiac screening. To address this issue, modified ECG interpretation criteria have become available for use within athletes.Entities:
Mesh:
Year: 2014 PMID: 25502812 PMCID: PMC4345900 DOI: 10.1136/heartjnl-2014-306437
Source DB: PubMed Journal: Heart ISSN: 1355-6037 Impact factor: 5.994
Electrocardiographic parameters used to define various ECG abnormalities in the European Society of Cardiology recommendations, Seattle Criteria and Refined Criteria
| ECG abnormality | European Society of Cardiology (ESC) recommendations | Seattle Criteria | Refined Criteria |
|---|---|---|---|
| Left atrial enlargement | Negative portion of the P-wave in lead V1 ≥0.1 mV in depth and ≥40 ms in duration | Prolonged P-wave duration of >120 ms in leads I or II with negative portion of the P-wave ≥0.1 mV in depth and ≥40 ms in duration in lead V1 | As ESC |
| Right atrial enlargement | P-wave amplitude ≥2.5 mm in leads II, III or aVF | As ESC | As ESC |
| Left QRS-axis deviation | −30° to −90° | As ESC | As ESC |
| Right QRS-axis deviation | >115° | >120° | As ESC |
| RV hypertrophy | Sum of R-wave in V1 and S-wave in V5 or V6 ≥1.05 mV | Sum of R-wave in V1 and S-wave in V5>1.05 mV and right axis deviation >120O | As ESC |
| Corrected QT interval | >440 ms (men) and >460 ms (women) | >470 ms (men) and 480 ms (women) | As Seattle |
| Complete left bundle branch block | QRS ≥120 ms predominantly negative QRS complex in lead V1 (QS or rS), and upright monophasic R-wave in leads I and V6 | As ESC | As ESC |
| Complete right bundle branch block | RSR pattern in anterior precordial leads with QRS duration ≥120 ms | Not relevant | As ESC |
| Intraventricular conduction delay | Any QRS duration >120 ms including RBBB and LBBB | Any QRS duration ≥140 ms or complete LBBB | As ESC |
| Pathological Q-wave | >0.4 mV deep in any lead except III, aVR | >0.3 mV deep and/or >40 ms duration in ≥2 leads except III and aVR | ≥40 ms in duration or ≥25% of the height of the ensuing R-wave |
| Significant T-wave inversion | ≥2 mm in ≥2 adjacent leads (deep)or ‘minor’ in ≥2 leads | >1 mm in depth in two or more leads V2−6, II and aVF or I and aVL (excludes III, aVR and V1) | As Seattle |
| ST-segment depression | ≥0.5 mm deep in ≥2 leads | As ESC | As ESC |
| Ventricular pre-excitation | PR interval <120 ms with or without delta wave | PR interval <120 ms with delta wave | As Seattle |
LBBB, left bundle branch block; mm, millimetres; ms, milliseconds; RBBB, right bundle branch block.
Figure 1Definition of an abnormal ECG using the Refined Criteria. AV, atrioventricular; LBBB, left bundle branch block; LVH, LV hypertrophy; ms, milliseconds; RBBB, right bundle branch block; PVC, premature ventricular contraction.
Performance comparison of three ECG interpretation criteria (ESC recommendations vs Seattle Criteria vs Refined Criteria)
| Combined | Arabic | Black | Caucasian | |
|---|---|---|---|---|
| Prevalence of an abnormal ECG using ESC recommendations | 555 (22.3%) | 261 (19.1%) | 224 (29.9%) | 70 (18.6%) |
| Prevalence of an abnormal ECG using Seattle Criteria | 289 (11.6%) | 133 (9.7%) | 124 (16.6%) | 32 (8.5%) |
| Prevalence of an abnormal ECG using Refined Criteria | 132 (5.3%) | 49 (3.6%) | 75 (10%) | 8 (2.1%) |
| Number of identified conditions associated with SCD | 10 (7 HCM; 3 WPW) | 4 (2 HCM; 2 WPW) | 6 (5 HCM; 1 WPW) | 0 |
| FPR when using ESC recommendations | 21.9% | 18.8% | 29.1% | 18.6% |
| FPR when using Seattle Criteria | 11.2% | 9.4% | 15.8% | 8.5% |
| FPR when using Refined Criteria | 4.9% | 3.3% | 9.2% | 2.1% |
ESC, European Society of Cardiology; FPR, false-positive rate; HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death; WPW, Wolff–Parkinson–White syndrome.
Sensitivity and specificity and likelihood ratios of three ECG interpretation criteria
| ESC | Seattle | Refined | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Combined athletes: | +ve ECG | −ve ECG | +ve ECG | −ve ECG | +ve ECG | −ve ECG | |||
| +ve path. | 10 | 0 | +ve path. | 10 | 0 | +ve path. | 10 | 0 | |
| −ve path. | 400 | 1308 | −ve path. | 213 | 1495 | −ve path. | 102 | 1606 | |
| Positive predictive value (%) (95% CI) | 2.4 (1.2 to 4.4) | 4.5 (2.2 to 8.1) | 8.9 (4.37 to 15.81) | ||||||
| Sensitivity (%) | 100 (69.0 to 100) | 100 (69.0 to 100) | 100 (69.0 to 100) | ||||||
| Specificity (%) | 76.6 (74.5 to 78.6) | 87.5* (85.9 to 89.1) | 94.0*† | ||||||
| Positive likelihood ratio | 4.3 (3.9 to 4.7) | 8.0* (7.1 to 9.1) | 16.8*† (13.9 to 20.2) | ||||||
| +ve ECG | −ve ECG | +ve ECG | −ve ECG | +ve ECG | −ve ECG | ||||
| +ve path. | 6 | 0 | +ve path. | 6 | 0 | +ve path. | 6 | 0 | |
| −ve path. | 168 | 383 | −ve path. | 90 | 461 | −ve path. | 54 | 497 | |
| Positive predictive value (%) (95% CI) | 3.4 (1.3 to 7.4) | 6.2 (2.3 to 13.1) | 10 (3.8 to 20.5) | ||||||
| Sensitivity (%) | 100 (54.1 to 100) | 100 (54.1 to 100) | 100 (54.1 to 100) | ||||||
| Specificity (%) | 69.5 (65.5 to 73.3) | 83.7 (80.3 to 86.7)* | 90.2 (87.4 to 92.5)*† | ||||||
| Positive likelihood ratio | 3.3 (1.8 to 3.6) | 6.1 (3.2 to 7.1)* | 10.2 (5.3 to 12.5)*† | ||||||
| +ve ECG | −ve ECG | +ve ECG | −ve ECG | +ve ECG | −ve ECG | ||||
| +ve path. | 4 | 0 | +ve path. | 4 | 0 | +ve path. | 4 | 0 | |
| −ve path. | 185 | 750 | −ve path. | 104 | 831 | −ve path. | 41 | 894 | |
| Positive predictive value (%) (95% CI) | 2.1 (0.6 to 5.3) | 3.7 (1.0 to 9.2) | 8.9 (2.5 to 21.2) | ||||||
| Sensitivity (%) | 100 (39.8 to 100) | 100 (39.8 to 100) | 100 (39.8 to 100) | ||||||
| Specificity (%) | 80.2 (75.6 to 82.7) | 88.9* (86.7 to 90.8) | 95.6*† (94.1 to 96.8) | ||||||
| Positive likelihood ratio | 5.1 (12.2 to 5.4) | 9.0* (3.8 to 10.1) | 22.8*† (9.4 to 28.8) | ||||||
*Significantly different from ESC recommendations.
†Significantly different from Seattle Criteria.
ESC, European Society of Cardiology; +ve ECG, abnormal ECG; −ve ECG, normal ECG; +ve path., identified cardiac pathology; −ve path., no identified cardiac pathology.